Understanding how engineered T cells work differently in cancer treatment
Dissecting intrinsic variability in engineered T Cell immunotherapies
This study is looking at how different types of engineered T cells, called CAR T cells, work for cancer patients, with the goal of finding the best ways to customize these treatments so they can help each person more effectively.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10985388 on NIH RePORTER |
What this research studies
This research investigates the variability in responses of engineered T cells, specifically Chimeric Antigen Receptor (CAR) T cells, in cancer patients. By developing new methods to test these T cells across a wide range of patients, the research aims to identify which specific modifications to the T cells can lead to better outcomes for individual patients. The approach includes screening various CAR T cell constructs and analyzing patient-specific responses to optimize treatment strategies. Ultimately, the goal is to create personalized immunotherapies that improve the effectiveness of cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients, particularly those with liquid tumors, who are considering or currently undergoing CAR T cell therapy.
Not a fit: Patients with solid tumors who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients using engineered T cells.
How similar studies have performed: Other research has shown promise in personalizing cancer immunotherapies, but this specific approach to dissecting T cell variability is relatively novel.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Roth, Theodore Lee — Stanford University
- Study coordinator: Roth, Theodore Lee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.